BetterLife Obtains TD-0148A Behavioural Pharmacology Data Confirming its Projected Non-hallucinogenic Property

NEXT STORY
Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers
PREV STORY
Takeda’s Area Offices in Dubai, United Arab Emirates Certified Sustainable and Inaugurated
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Intermountain Healthcare Partners With the University of Utah to Create Academic Program to Help Keep People Healthy

author_avatar
NASDAQ Market News

New data supports development of colchicine for the prevention of acute respiratory distress syndrome

author_avatar
NASDAQ Market News

Paratek Demonstrates Breadth of Omadacycline Clinical and Microbiological Data at ASM Microbe 2018

Poster presentations will include new analysis of efficacy against drug resistant S. aureus in ...

author_avatar
NASDAQ Market News